Association of Genetic Polymorphisms of MTHFR and Methotrexate-related Adverse Reaction

Abstract

Abstract: Objective To investigate the association between methylentetrahydrofolate (MTHFR) C677T and A298C genetic polymorphisms and the adverse reaction after high-dose methotrexate(MTX) chemotherapy in Chinese cancer patients. Methods Total 102 inpatients receiving high-dose MTX chemotherapy were recruited in which the 62 acute lymphoblastic leukemia ( ALL ) patients were treated with 24h -intravenous injection of MTX1～3g / 21d and the 40 osetosarcoma patients were treated with 24h -intravenous injection of MTX8～10g/21d. The genotype of MTHFR C667T and A298C was analyzed by real-time qPCR. The relation between genotypes and adverse reactions was analyzed. Results The frequency of MTHR 667TTwas significantly higher in ALL patients experienced adverse reaction than that in the ALL patients without adverse reaction(34.1% vs 11.1%, P=0.025). Conclusion MTHR C667T genetic polymorphism was associated with MTX-related adverse reaction.

Key words: methotrexate, methylentetrahydrofolate, genetic polymorphism, adverse reaction

CLC Number:

R979.12
R917

ZHOU Xin-ke, SHU Wen-ying ,LIANG Min ,HE Lu. Association of Genetic Polymorphisms of MTHFR and Methotrexate-related Adverse Reaction [J]. Chinese Journal of Pharmacovigilance, 2013, 10(11): 647-649.

References

[1] Plaza-Plaza J C, Aguilera M, Canadas-Garre M, et al. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis[J]. OMICS, 2012, 16(11): 589-595.
[2] Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia[J/OL].（2012-10-23）[2013-11-15]. www.ncbi.nlm.nih.gov/pubmed/23089671.
[3] Galbiatti A L, Castro R, CaldasH C, et al. Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate[J/OL]. (2013-07-10)[2013-11-15].www.ncbi.nlm.nih.gov/pubmed/23838799.
[4] Avivi I, Zuckerman T, Krivoy N, et al. Genetic Polymorphisms Predicting Methotrexate Blood Levels and Toxicity in Adult Non-Hodgkin'sLymphoma[J/OL].(2013-08-13)[2013-11-15].www.ncbi.nlm.nih.gov/pubmed/23829278.
[5] Davila-Fajardo C L, Swen J J, Cabeza Barrera J, et al. Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate[J].Pharmacogenomics,2013, 14: 63-73.
[6] 郑苗苗,岳丽杰,陈小文,等. 急性淋巴细胞白血病患儿MTHFR基因多态性与大剂量甲氨蝶呤毒副反应的关系[J]. 中国当代儿科杂志, 2013, 15(3): 201-206.
[7] Choe J Y, Lee H, Jung H Y, et al. Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis[J]. Rheumatol Int, 2012, 32(6): 1837-1842.
[8] Mena JP, Salazar-Paramo M, Gonzalez-Lopez L, et al. Polymorphisms C677Tand A1298Cin theMTHFRgene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases[J]. Pharmacogenomics J, 2011, 11(4): 287-291.
[9] Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications[J].Mutat Res,2005, 573(1-2):180-194.
[10] Tasbas O, Borman P, Gurhan Karabulut H, et al. The Frequency of A1298C and C677T Polymorphisms of the Methylentetrahydrofolate Gene in Turkish Patients with Rheumatoid Arthritis: Relationship with Methotrexate Toxicity[J].Open Rheumatol J, 2011, 5: 30-35.

[1]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
[2]	GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
[3]	ZHANG Li, WANG Yujia, ZHANG Lingling, CHEN Jiaxin, LIN Minhua, LIN Xiaohui, NIE Xuekun. Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1035-1038.
[4]	YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo. Risks of safety Qingkailing oral preparation [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
[5]	ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling. Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
[6]	YANG Le, XIA Dongsheng, WANG Tao. Risks to safety of vitamin B₆ injection [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
[7]	LUO Fangmei, WU Pan, LI Jing, WANG Ting, WANG Fangjie. Correlations of ABCB1 C3435T genetic polymorphism with serum concentrations and adverse reactions of high-dose methotrexate in children with mature B-cell lymphoma [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 675-679.
[8]	JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin. Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
[9]	LIU Zhike, ZHAN Siyan. Progress in applications of self-controlled designs in association study of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
[10]	YUAN Xiaolong, WAN Qihua, TAO Donghong, QI Hao, WANG Aixia. Pharmaceutical care of a severely poisoned patient with methotrexate tablets [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 924-928.
[11]	LI Yu, FAN Huihui, FENG Xiaojun, ZHANG Yonghuang, CHEN Qin, WANG Yunhong, CHEN Chuantao, ZHANG Lei, SHI Tianlu. Association between ABCB1 C3435T polymorphisms and methotrexate-induced toxicity in childhood acute lymphoblastic leukemia: Meta analysis [J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 421-425.
[12]	CHEN Fangfang, ZHANG Hongxu. Pharmacy practice during the treatment of primary central nervous system lymphoma with high dose methotrexate [J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 446-449.
[13]	CUI Can, WEI Hongtao, CHENG Sheng, SHEN Su. Adverse reactions induced by teriparatide [J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 333-335.
[14]	LIU Min, PEI Xiaojing, WANG Haixue. Problems with and suggestions about expedited reporting of suspected unexpected serious adverse reactions during clinical trials of drugs in China [J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 176-179.
[15]	WU Chen, LIU Cuili, WANG Tao. Cardiovascular safety of haloperidol preparations [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1100-1102.